# Invenshure, LLC

> Invenshure is a Minneapolis venture studio that licenses original intellectual property from research institutions like the Mayo Clinic, University of Minnesota, and Stanford, then builds companies around it with in-house scientists, engineers, and operators. Since 2011 it has spun up ventures in medical imaging AI, pharmacogenomics, industrial IoT, and precision oncology, including OneOme, Imbio, Flywheel, Exosite, and MEKanistic Therapeutics.

- **Founded:** 2011
- **Headquarters:** Minneapolis, United States
- **Founders:** Troy Kopischke (Co-CEO & Co-Founder), Danny Cunagin (Co-CEO & Co-Founder)
- **Team size:** 34 employees
- **Products:** Venture studio / company building, OneOme, Imbio, Flywheel, Exosite
- **Notable:** Co-founded 7 companies and exited 3 since 2011., Portfolio company OneOme named #2 of 2018 World's Most Innovative Biotech Companies by Fast Company., Portfolio company Imbio acquired by 4DMedical.

## Products & services

- **Venture studio / company building** — Licenses original IP from research institutions and builds companies around it using in-house scientists, engineers, and operators.
- **OneOme** — Pharmacogenomics company launched with the Mayo Clinic; genome-based prescription drug advisor. Named #2 of 2018 World's Most Innovative Biotech Companies by Fast Company.
- **Imbio** — Automated medical image analysis and cardiothoracic diagnostics; acquired by 4DMedical.
- **Flywheel** — Research data management and machine learning platform for scientific and clinical imaging data.
- **Exosite** — Industrial Internet of Things (IoT) cloud data platform for remote equipment monitoring.
- **MEKanistic Therapeutics** — Precision oncology company built around a dual PI3K/EGFR inhibitor (MTX-531); FDA cleared its IND in May 2026.
- **GeneMatters** — Telegenetic counseling services company; later exited.

## Achievements

- Co-founded 7 companies and exited 3 since 2011.
- Portfolio company OneOme named #2 of 2018 World's Most Innovative Biotech Companies by Fast Company.
- Portfolio company Imbio acquired by 4DMedical.
- Launched MEKanistic Therapeutics (2022); its MTX-531 cancer drug cleared FDA IND in May 2026, enabling a Phase 1 trial.
- Founders previously built Steady State Imaging, sold to GE Healthcare in 2011.
- Launched a $50 million second fund in 2015.
- Co-founder Troy Kopischke won the Impact Entrepreneur Award.

## Latest updates

- **2026-05** — MEKanistic Therapeutics announced FDA clearance of its IND for MTX-531, enabling a Phase 1 trial in advanced solid tumors; first-patient dosing anticipated Q3 2026.
- **2024** — MTX-531 preclinical findings published in Nature Cancer, showing dual EGFR/PI3K inhibition and durable tumor regressions.
- **2022-06** — Invenshure launched MEKanistic Therapeutics, a precision oncology company.

## Links

- Website: https://invenshure.com
- LinkedIn: https://www.linkedin.com/company/invenshure-llc
- Facebook: https://m.facebook.com/Invenshure.hu

---

Profile page: https://yespress.io/invenshure-llc
Published by YesPress — https://yespress.io
Last updated: 2026-08-19